Publications

• Kenneth Chahine (date unknown). Amgen battles for EPO in Congress. Nature Biotechnology, Nov;16:999-1000 (1998). Accepted, .
• Kenneth Chahine (date unknown). The importance of "legalese" in biotechnology patents. Nature Biotechnology, Oct;16: 971-2(1998). Accepted, .
• Kenneth Chahine (date unknown). Hatch-Waxman changes debated. Nature Biotechnology, Jul;18: 710-1(2000). Accepted, .
• Kenneth Chahine (date unknown). Building the proper foundation for genomic based patents, Nature Biotechnology, 16: 683-684 (1998). Accepted, .
• Kenneth Chahine (date unknown). Industry opposes genomic legislation. Nature Biotechnology, May;20: 419 (2002). Accepted, .
• Kenneth Chahine (date unknown). Amgen preserves erythropoietin monopoly for now. Nature Biotechnology, Mar;19: 188 (2001). Accepted, .
• Kenneth Chahine (date unknown). All clear for HIV-targeting ribozyme in phase II. Nature Biotechnology, Feb;16:123(1998). Accepted, .
• Kenneth Chahine (date unknown). Cancer prognostic approved. Nature Biotechnology, Feb;16:121(1998). Accepted, .
• Kenneth Chahine (date unknown). Patent office resurrects EST debate, Nature Biotechnology, 16: 711 (1998). Accepted, .
• Kenneth Chahine (date unknown). Genentech sues to protect clot buster market share, Nature Biotechnology, 16: 410 (1998). Accepted, .
• Kenneth Chahine (date unknown). Elanex battles for piece of erythropoietin market, Nature Biotechnology, 16: 16 (1998). Accepted, .
• Kenneth Chahine (date unknown). US courts disagree on generic exclusivity, Nature Biotechnology, 16: 132 (1998). Accepted, .
• Kenneth Chahine (date unknown). Going beyond the native: Protecting DNA and protein patents, Nature Biotechnology, 15: 183-185 (1997). Accepted, .
• Kenneth Chahine (date unknown). Enabling DNA and Protein Claims: Why Claiming Biological Equivalents Encourages Innovation, American Intellectual Property Law Association Quarterly Journal, 25(3): 333 (1997). Accepted, .
• Kenneth Chahine (date unknown). Wrangling over the rights to BRAC1, Nature Biotechnology, 15: 936 (1997). Accepted, .
• Kenneth Chahine (date unknown). Eli Lilly Wins on Appeal, Nature Biotechnology, 15: 823 (1997). Accepted, .
• Kenneth Chahine (date unknown). Patenting Genes: Just when you thought it was safe, Nature Biotechnology, 15: 586-587 (1997). Accepted, .
• Kenneth Chahine (date unknown). Amgen Protects its Billion Dollar Protein, Nature Biotechnology, 15: 496-497 (1997). Accepted, .
• Kenneth Chahine (date unknown). University of Colorado wins inventorship dispute with American Cyanamid, Nature Biotechnology, 15: 831 (1997). Accepted, .
• Kenneth Chahine (date unknown). An Industry in Focus: Utah's Biotechnology Boom, Utah Business, October: 27-31 (1997). Accepted, .
• Kenneth Chahine (date unknown). Electrical Activity Suppresses Nicotinic Acetylcholine Receptor Gamma Subunit Promoter Activity. Developmental Biology, 168: 416-428 (1995). Accepted, .
• Kenneth Chahine (date unknown). Calcium Regulates the Expression of the Nicotinic Acetylcholine Receptor Subunit RNAs, Journal of Biological Chemistry, 269: 19447-19456, (1994). Accepted, .
• Kenneth Chahine (date unknown). Coupling Muscle Electrical Activity to Nicotinic Acetylcholine Receptor Gene Expression Via a Cyclic AMP-Dependent Second Messenger System, Journal of Biological Chemistry, 268, 2893-2898, (1993). Accepted, .
• Kenneth Chahine (date unknown). Molecular and electrophysiological characterization of the allelic variant of the rat alpha-6 GABA-A receptor subunit, Molecular Brain Research, 16, 173-178, (1992). Accepted, .
• Kenneth Chahine (date unknown). A 102 Base Pair Sequence Confers Electrical Regulation on the Nicotinic Acetylcholine Receptor (nAChR) Delta-Subunit, Development, 12 , 123-128, (1992). Accepted, .